(2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S)-4,5-Dihydroxy-3-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol

Term ID

CHEBI:154951

Synonyms

alpha-L-arabino-pentopyranosyl-(1->2)-alpha-L-arabino-pentopyranosyl-(1->4)-beta-D-gluco-hexopyranose
Ara(a1-2)Ara(a1-4)b-Glc

Definition

References

glytoucan:G91010HW

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S)-4,5-Dihydroxy-3-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol

Phenotype where environments contain (2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S)-4,5-Dihydroxy-3-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol

Phenotype modified by environments containing (2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S)-4,5-Dihydroxy-3-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol

Phenotype affecting (2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S)-4,5-Dihydroxy-3-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol

Human Disease Model